RATIONALE: Compared to nonsmokers, smokers exhibit a number of potentially important differences in regional brain structure including reduced gray matter (GM) volume and/or density in areas including frontal and cingulate cortices, thalamus, and insula. However, associations between brain structure and smoking cessation treatment outcomes have not been reported. OBJECTIVES: In the present analysis we sought to identify associations between regional GM volume--as measured by voxel-based morphometry (VBM)--and a smoking cessation treatment outcome (point prevalence abstinence at 4 weeks). METHODS: Adult smokers underwent high-resolution anatomical MRI scanning prior to an open label smoking cessation treatment trial. VBM was conducted in SPM5 using the DARTEL algorithm and relapser vs. quitter groups were compared using independent sample t tests (p < 0.001, uncorrected). Analyses controlled for potentially confounding factors including years smoked, cigarettes per day, total intracranial volume (TIV), and sex. RESULTS: Of 18 smokers, 8 achieved a 4-week point prevalence abstinence, confirmed by CO level (<or=8 ppm). After controlling for all covariates, compared to relapsers, quitters had significantly higher GM volume in the left putamen and right occipital lobe, while also significantly lower GM volume in bilateral hippocampus and right cuneus. CONCLUSIONS: These preliminary results suggest that maintaining smoking abstinence is associated with higher pre-quit brain volume in regions that subserve habit learning and visual processing, and lower brain volume in regions that subserve long-term memory processes and visual information processing. Future, large-scale studies can determine whether brain structure variables can serve as clinically useful predictors of smoking cessation treatment outcome.
RATIONALE: Compared to nonsmokers, smokers exhibit a number of potentially important differences in regional brain structure including reduced gray matter (GM) volume and/or density in areas including frontal and cingulate cortices, thalamus, and insula. However, associations between brain structure and smoking cessation treatment outcomes have not been reported. OBJECTIVES: In the present analysis we sought to identify associations between regional GM volume--as measured by voxel-based morphometry (VBM)--and a smoking cessation treatment outcome (point prevalence abstinence at 4 weeks). METHODS: Adult smokers underwent high-resolution anatomical MRI scanning prior to an open label smoking cessation treatment trial. VBM was conducted in SPM5 using the DARTEL algorithm and relapser vs. quitter groups were compared using independent sample t tests (p < 0.001, uncorrected). Analyses controlled for potentially confounding factors including years smoked, cigarettes per day, total intracranial volume (TIV), and sex. RESULTS: Of 18 smokers, 8 achieved a 4-week point prevalence abstinence, confirmed by CO level (<or=8 ppm). After controlling for all covariates, compared to relapsers, quitters had significantly higher GM volume in the left putamen and right occipital lobe, while also significantly lower GM volume in bilateral hippocampus and right cuneus. CONCLUSIONS: These preliminary results suggest that maintaining smoking abstinence is associated with higher pre-quit brain volume in regions that subserve habit learning and visual processing, and lower brain volume in regions that subserve long-term memory processes and visual information processing. Future, large-scale studies can determine whether brain structure variables can serve as clinically useful predictors of smoking cessation treatment outcome.
Authors: Arthur L Brody; Mark A Mandelkern; Murray E Jarvik; Grace S Lee; Erlyn C Smith; Joe C Huang; Robert G Bota; George Bartzokis; Edythe D London Journal: Biol Psychiatry Date: 2004-01-01 Impact factor: 13.382
Authors: Brian L Carter; Jason D Robinson; Cho Y Lam; David W Wetter; Jack Y Tsan; Susan X Day; Paul M Cinciripini Journal: Nicotine Tob Res Date: 2006-06 Impact factor: 4.244
Authors: Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2008-11-08 Impact factor: 6.556
Authors: P Brambilla; K Harenski; M A Nicoletti; A G Mallinger; E Frank; D J Kupfer; M S Keshavan; J C Soares Journal: Psychiatry Res Date: 2001-04-10 Impact factor: 3.222
Authors: Colleen A Hanlon; Max M Owens; Jane E Joseph; Xun Zhu; Mark S George; Kathleen T Brady; Karen J Hartwell Journal: Addict Biol Date: 2014-08-13 Impact factor: 4.280
Authors: Sarah W Yip; Elise E DeVito; Hedy Kober; Patrick D Worhunsky; Kathleen M Carroll; Marc N Potenza Journal: Drug Alcohol Depend Date: 2014-04-13 Impact factor: 4.492
Authors: Bridgin G Lee; Agustin Anastasia; Barbara L Hempstead; Francis S Lee; Julie A Blendy Journal: Nicotine Tob Res Date: 2015-03-05 Impact factor: 4.244
Authors: David W Frank; Paul M Cinciripini; Menton M Deweese; Maher Karam-Hage; George Kypriotakis; Caryn Lerman; Jason D Robinson; Rachel F Tyndale; Damon J Vidrine; Francesco Versace Journal: Nicotine Tob Res Date: 2020-07-16 Impact factor: 4.244
Authors: K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur Journal: Clin Pharmacol Ther Date: 2013-03-18 Impact factor: 6.875